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A B S T R A C T
Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and mortality despite ex-
cellent pharmacological and revascularization approaches. Low-density lipoproteins (LDL) are undoubtedly the
most significant biochemical variables associated with atheroma, however, compelling data identify inflamma-
tion as critical for the maintenance of the atherosclerotic process, underlying some of the most feared vascular
complications. Although its causal role is questionable, high-sensitivity C-reactive protein (hs-CRP) represents a
major biomarker of inflammation and associated risk in CVD. While statin-associated reduced risk may be related
to lowering of both LDL-C and hs-CRP, PCSK9 inhibitors leading to dramatic LDL-C reductions do no alter hs-CRP
levels. On the other hand, hs-CRP levels identify groups of patients with a high risk of CV disease achieving bet-
ter ASCVD prevention in response to PCSK9 inhibition. In the FOURIER study, even in patients with extremely
low levels of LDL-C, there was a stepwise risk increment according to the values of hs-CRP: +9% (<1 mg/L),
+10.8% (1–3 mg/L) and +13.1% (>3 mg/L). Likewise, in the SPIRE-1 and -2 studies, bococizumab patients
with hs-CRP> 3 mg/L had a 60% greater risk of future CV events. Most of the patients enrolled in the PCSK9
trials were on maximally tolerated statin therapy at baseline, and an elevated hs-CRP may reflect residual in-
flammatory risk after standard LDL-C lowering therapy. Moreover, data on changes in inflammation markers in
carriers of PCSK9 loss-of-function mutations are scanty and not conclusive, thus, evidence from the effects of
anti-inflammatory molecules on PCSK9 levels might help unravel this hitherto complex tangle.
1. Introduction
Studies on myocardial infarction (MI) patients have clearly estab-
lished that all post-MI patients are at increased risk for recurrence of
events, despite early revascularization and well established pharmaco-
logical therapies [1]. Among patients with clinically manifest vascular
disease, more than 20% showed a risk of recurrent events in the ex-
cess of 30% over 10 years, including MI, stroke, or vascular death, thus
indicating an area of unmet medical need [2]. The persistence of high
risk has been increasingly associated with elevated levels of proinflam-
matory molecules, such as cytokines and acute-phase reactants [3]. In-
deed, beyond the well-known role of LDL in atherosclerosis, data from
the proof-of-concept CANTOS (Canakinumab Anti-Inflammatory Throm-
bosis Outcome Study) trial [4] have clearly identified inflammation as
one of the key biological processes of atherosclerosis.
Low-density lipoproteins (LDL) represent the most significant bio-
chemical variable associated with atheroma. The extent of lowering
of LDL-C and cardiovascular (CV) risk reduction has been evaluated
across different statin and non-statin therapies. The relative risk reduc-
tion of major vascular events was similar for all drug classes (statins, bile
acid sequestrants, ezetimibe, and fibrates), and the achieved lowering of
LDL-C was associated with a reduced incidence of major CV events [5].
The CV risk linked to increased inflammatory markers was well es-
tablished following the detection of elevated high sensitivity C-reactive
protein (hs-CRP) in post MI patients with a residual inflammatory risk
[6]. This initial observation in patients with relatively normal lipopro-
tein profile and positive response to statins gave the first rationale for
the validity of the approach [7]. CRP is a liver-derived acute phase pro-
tein associated with inflammation. Being readily assayable in the cir-
culation, it has reached an established role in the evaluation of bacte-
rial infections, but also of the clinical status of generalized inflamma-
tory diseases. Among these, foremost is rheumatoid arthritis, followed
by chronic diseases such as spondylitis, lupus and others [8].
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High sensitivity (hs)-CRP >2mg/L associates with major CV risk
markers, such as elevated LDL-C, as well as to the progression of CV le-
sions [9], although the existence of a well defined threshold is disputed
[10,11]. Use of this marker for an early detection of lesions and, more
importantly, for the monitoring of agents reducing CV risk, has gained
wide acceptance. Clinical studies on statins, in particular, have shown
that also patients with coronary disease not associated with marked hy-
percholesterolemia, benefit from the reduction of hs-CRP [12].
Overall, although the earlier meta-analysis of Kinlay et al. [13] sup-
ported a strong correlation between LDL-C reduction and lowering of
hs-CRP, the case is certainly different for the newly developed PCSK9
antagonists. With these, a dramatic reduction of LDL-C, in the range of
50–60%, is not associated with any changes in hs-CRP. Thus, the present
review will discuss the evidence linking PCSK9 and inflammation with
a particular emphasis on hs-CRP a marker of residual inflammatory CV
risk, especially in secondary prevention.
2. Lipid mediated-inflammation
A number of studies have described pathways leading to vascular in-
flammation in atherosclerosis. Flow perturbations on endothelial cells
(EC), particularly at areas of complex geometry, predispose to lesion de-
velopment [14]. These areas express adhesion molecules and inflamma-
tory genes to a higher extent [15]. In vessels with compromised glyco-
calyx, LDL penetrate the arterial intima via endothelial vesicles (tran-
scytosis) or open endothelial junctions [16]. Lipoproteins <70nm in
diameter, i.e. all HDL, LDL and intermediate-density lipoprotein (IDL)
particles, in addition to very-low density lipoprotein (VLDL) and small
chylomicron remnants, can pass the endothelial barrier and enter in-
tima directly from the circulation [17]. Once in the arterial suben-
dothelium, lipoproteins are trapped by subendothelial proteoglycans
through a charge-based interaction [18,19]. LDL then undergo oxida-
tion by the combined action of lipoxygenases, reactive oxygen species,
peroxynitrite, and/or myeloperoxidase [20]. OxLDL and LDL-derived
oxidized phospholipids further stimulate the inflammatory activation of
macrophages and vascular smooth muscle cells; they provide also ox-
idation-specific epitopes (OSEs) recognized by the C-reactive protein,
complement system proteins and innate “natural” IgM antibodies [21].
OxLDL stimulate endothelial cells by inducing the expression of cell
surface adhesion molecules that mediate the rolling and adhesion of
blood leukocytes (monocytes and T cells) [22]. OxLDL are rapidly rec-
ognized by macrophage scavenger receptors, leading to the formation of
lipid-laden foam cells; scavenger receptor uptake is not subject to feed-
back inhibition by intracellular sterols, and phagocytosis and/or recep-
tor uptake can continue unabated [23]. OxLDL are immunogenic by pre-
senting different lipid peroxidation-derived structures, such as oxidized
phospholipids and malondialdehyde that are recognized as antigens by
the immune system [24]. These oxidized products thus act as targets of
innate immunity and as critical modulators of inflammatory responses
[25].
Although foam cell populations in atherosclerotic lesions have been
considered as primarily of leukocyte origin, smooth muscle cells (SMC)
contribute significantly to foam cell populations in human atheroma,
50% of foam cells being SMC-derived [26]. Among scavenger recep-
tors, the LDL receptor-related protein 1 (LRP1) is a key mediator of ag-
gregated LDL-induced cholesteryl ester accumulation in SMCs [27], ex-
pressed in both SMCs and macrophages of human atherosclerotic lesions
[28].
The activated endothelium allows the entry to the intima of
bone-marrow-derived monocytes, e.g. the Ly6Chi subpopulation, which
differentiate into macrophages. As a result of the activation of inflam-
matory macrophages and dendritic cell (DC), an inflammatory adap
tive immune response involving T helper cells (Th1), but also Th17, Th2
as well as B cells develops [29].
After entering macrophages through scavenger receptor CD36,
ox-LDL can prime and activate the innate immune signaling complex
NOD-like receptor pyrine domain-containing protein 3 (NLRP3) inflam-
masome in macrophages, induced by cholesterol crystallization [30].
Cholesterol crystal formation is consequent to an imbalance between es-
terified and free cholesterol and by changes in HDL function [31]. Upon
activation by different endogenous triggers abundantly present in ath-
erosclerotic lesions, e.g. cholesterol crystals [32], NLRP3 leads to an in-
creased secretion of IL-1β [33]. IL-1 stimulates adhesion molecules that
recruit leukocytes as well as chemokines, e.g. monocyte chemoattractant
protein (MCP)-1 (C–C motif chemokine ligand [CCL]-2). Reduction of
cholesterolemia reduces cholesterol crystal formation and, as a conse-
quence, atheromas. Whether reduction of the inflammatory potential of
macrophages may occur in the absence of NLRP3 activation remains an
open question [34].
In addition to the well established role of LDL-C [35], the contribu-
tion of triglycerides (TG) to a raised CV risk has become clear both after
long-term prospective studies [36] and a recent mendelian randomiza-
tion analysis [37]. TG-rich lipoproteins may penetrate the arterial wall
and are retained within the sub-endothelial space; after oxidative mod-
ification they may lead to the development of atherosclerotic plaques.
Lipolysis of TG-rich lipoproteins may release oxidized free-fatty acids
(FFA) and lysolecithin, further stimulating endothelial cell inflammation
and coagulation [38]. A post-hoc evaluation of the REDUCE-IT study
[39] reports a significant reduction of CV events in patients with hyper-
triglyceridemia treated with high dose EPA, and indicates that even low
levels of plasma TG, e.g. between 81 and 131mg/dL can carry a CV risk
[39].
3. PCSK9 contribution to the development of atherosclerosis
Besides the role of PCSK9 in the regulation of LDL-C, its expression
in endothelial cells, VSMC and, at a low level, in macrophages [40],
implies the potential role of PCSK9 in atherosclerosis plaque develop-
ment (Fig. 1). VSMC produce more PCSK9 than endothelial cells, es-
pecially in response to shear stress [41]. In particular, VSMC of human
atherosclerotic plaques secrete PCSK9, that acts in a paracrine manner
on vessel macrophages by reducing LDLR expression and LDL uptake
[42]. Thus, PCSK9 may be a possible determinant of LDL retention in
the intima of arterial walls [43]. In line with these findings, a positive
association between PCSK9 and arterial stiffness - a parameter associ-
ated with the presence of carotid plaques - has been described [44], a
conclusion further supported by a study in patients of Italian ancestry
in whom short-term therapy with monoclonal antibodies improved en-
dothelial function [45] and arterial stiffness [46].
The hypothesis that PCSK9 may affect atherosclerosis in a man-
ner not exclusively related to lipid changes was assessed in models of
LDLR−/− or apoE−/− mice overexpressing human PCSK9 (hPCSK9). This
latter accumulates in the arterial walls and can directly affect athero-
sclerotic lesion size and composition independent of lipid and lipopro-
tein changes [47]. These findings go together with those reporting
that bone marrow macrophages derived from hPCSK9 mice progres-
sively accumulate in lesions of apoE−/− recipient mice with a markedly
raised infiltration of Ly6C (hi) inflammatory monocytes (+32%) [48].
In line with these findings, PCSK9−/− mice are partially protected from
neointimal plaque formation, further supporting an effect of PCSK9
on intimal thickening [49]. A direct clinical translation of these find-
ings comes from the ATHEROREMO-IVUS (The European Collabora-
tive Project on Inflammation and Vascular Wall Remodeling in Ath-
erosclerosis – Intravascular Ultrasound)
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Fig. 1. Possible pleiotropic effects of PCSK9 inhibition in atherosclerosis. Reproduced with permission from Nature Springer [148].
study, showing that higher PCSK9 levels are linearly associated with a
higher necrotic core fraction in coronary atheromas [50].
A distinct conclusion on this topic came from a recent study report-
ing that in an atherosclerosis-prone mouse model, the deletion of Pcsk9
gene reduced atherogenesis via mechanisms independent of LDLR. In-
deed, endothelial cells exposed to lipoproteins from these animals ex-
pressed fewer adhesion molecules, such as Icam-1, and chemotactic fac-
tors, e.g. Ccl2 (Mcp-1) and Ccl-7 (Mcp-3), all promoting monocyte adhe-
sion and infiltration into the vessel wall [51].
The pro-atherogenic role of PCSK9 was further supported by find-
ings which demonstrated that PCSK9 directly alters cholesterol home-
ostasis in macrophages by inhibiting ATP-binding cassette transporter
ABCA1 mediated cholesterol efflux [52]. Indeed, lipid accumulation in
the artery wall depends on a balance between entry and egress. An-
other facet of the association among inflammation, PCSK9, and athero-
sclerosis relates to ox-LDL. Dendritic cells (DC) from vulnerable carotid
plaques induce PCSK9 when exposed to OxLDL; in a feed-forward loop
PCSK9 stimulates DC maturation, pro‐inflammatory cytokine produc-
tion and T‐cell proliferation [53]. Inhibition of PCSK9, in turn, re-
verts the effects of OxLDL by decreasing production of inflammatory cy-
tokines, e.g. TNF-α, IL-1 β and IL-6 [53]. In a previous study evaluat-
ing the contribution of the TLR4/NF-kB pathway, PCSK9 overexpression
in macrophages upregulated TLR4 expression with a higher NF-kB nu-
clear translocation, followed by a raised secretion of proinflammatory
cytokines mediated by OxLDL [54]. In human primary macrophages,
exposure to human recombinant PCSK9 upregulated pro-inflammatory
cytokine and chemokine genes, e.g. IL-1β, IL-6, TNF-α, CXCL2, and
MCP1, once again showing a pro-inflammatory behavior linked to PC-
SK9 [55]. In this scenario, the positive feedback between PCSK9 and
LOX-1 - a scavenger receptor responsible for binding, internalization
and degradation of OxLDL - should not be underestimated. In arte-
rial tissues and cultured ECs and SMCs, mitochondrial ROS genera-
tion exacerbates a positive cross-talk between PCSK9 and LOX-1, in
which PCSK9 stimulates LOX-1 and LOX-1 stimulates PCSK9 [56]. This
process may contribute to atherogenesis, considering that PCSK9 stim-
ulates the expression of other scavenger receptors, e.g. scavenger re-
ceptors class A (SRA) and CD36 [57]. The relationship between
PCSK9 and vascular inflammation was further investigated in the
APOE*3Leiden.CETP mice: vascular inflammation (by reducing T cell
accumulation in aortic plaques) and necrotic core formation were at-
tenuated upon treatment with PCSK9 monoclonal antibody alirocumab
[58] or an anti-PCSK9 vaccine [59].
When considering immune cells and atherosclerosis, there is now ev-
idence that LDL-lowering by PCSK9 inhibition can reduce accumulation
of lipid droplets in monocytes, counteracting both lipid-induced mono-
cyte activation and reactivity [60]. Monocytes from FH patients intol-
erant to statins show a pro-inflammatory and migratory signature with
an increased intracellular lipid droplet accumulation. Given the role of
monocytes, and the interaction between chemokines (e.g. CCL2) and
chemokine receptors (e.g., CCR2) in atherosclerosis development, these
findings highlight how PCSK9 inhibition might alter the inflammatory
response aside from hs-CRP changes [60]. These conclusions support the
notion that severe hyperlipidaemia leads to increased intracellular lipid
accumulation and foamy monocyte formation. Foamy monocytes can
enhance monocyte migration from the circulation into the arterial walls,
accelerating differentiation into foamy macrophages, thus contributing
to the development of atheromas [61].
Whether reduction in immune cell activity following LDL-C and
Lp(a) lowering by PCSK9 inhibition will translate into decreased in-
flammation in atherosclerotic lesions has been addressed in the An-
itschkow Study. This trial enrolled coronary patients with elevated
Lp(a)>50mg/dL, LDL-C≥100mg/dL and arterial wall inflammation as
assessed by the most diseased target-to-background ratio (MDS-TBR)
≥1.6 on 18F-fluoro-deoxyglucose positron-emission tomography/com-
puted tomography (FDG-PET/CT). A 16-week treatment with
evolocumab (420 mg/every 4 weeks) reduced LDL-C by 61% with a
14% Lp(a) lowering and no evidence of reduction of hs-CRP or of
arterial inflammation (MDS-TBR -8.3% for evolocumab vs −5.3% for
placebo) [62]. Considering that hs-CRP seems not to correlate with ar-
terial wall inflammation [63], Lp(a) may be a better marker linked
to pro-inflammatory changes. Lp(a) likely contributes to CVD risk be-
ing more atherogenic than LDL since it contains both the proathero-
genic components of LDL and the oxidized phospholipids (OxPL), abun-
dant in the apo(a) tail [64]. OxPL are crucial me
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diators of the arterial wall inflammation process among patients with
elevated Lp(a) [65]. However, the role of raised plasma Lp(a) levels
in thrombosis remains controversial (reviewed in Ref. [66]). Genetic,
epidemiological and clinical studies have, however, firmly established
that elevated concentrations of Lp(a) are an independent and proba-
bly causal CV risk factor. In the FOURIER study, evolocumab signifi-
cantly reduced Lp(a) levels (median changes −26.9%), and patients with
higher baseline Lp(a) levels benefitted more in terms of absolute Lp(a)
reduction [67]. In the ODYSSEY OUTCOMES trial, absolute changes in
Lp(a) increased progressively with increasing quartile: −5.12%, −9.8%
and −20.2%, being the overall Lp(a) reductions associated with CV risk
reduction (commented in Ref. [68]).
4. Correlations between hs-CRP and CV risk
Questions on the validity of hs-CRP as a causal determinant of CV
risk have been raised because of the absence, in particular, of genetic
loci associated with hs-CRP levels and with the occurrence of CV events,
in contrast to neighboring loci such as IL-6R or the APOCI-CII clus-
ter [69]. Mendelian randomization analysis of single polymorphisms
showed elevation in hs-CRP concentrations without an increased risk
of CHD, a finding discordant with the risk ratio [1.33 (1.23–1.43)] ob-
served for CHD per 1 SD higher hs-CRP found in prospective studies
[70]. Null associations among hs-CRP-related and actual risk of CHD
were found also in a genome-wide association study demonstrating
no association between genetically elevated hs-CRP levels and risk of
CHD [71]. Although hs-CRP may be considered unquestionably a good
marker of CV risk [72], the evidence for causality is uncertain. In hu-
mans, C-reactive protein is a relatively moderate predictor of coronary
heart disease [73] and when infused into healthy adults no meaning-
ful increment in proinflammatory cytokine levels has been found [74].
These conclusions were in line with those of different experimental mod-
els in which transgenic expression of human or rabbit CRP [75–77] or
CRP deletion [78] did not support any proatherogenic role of this pen-
traxin. On the other hand, the biological basis recognizing hs-CRP as a
biomarker of CV risk has been, very recently, further reinforced in acute
coronary syndrome patients with LDL-C of 64.9mg/dL and hs-CRP >
2.4mg/L; the initial and serial measurements of hs-CRP provided a very
effective tool for the identification of patients at higher risk for mortality
and morbidity, independent of optimal evidence-based pharmacological
therapies [79].
Elevated hs-CRP levels are definitively associated to an increased
CV risk and their reduction by statins is beneficial. However, there is
no agreement so far as to whether the two variables, i.e. reduction of
LDL-C and hs-CRP, are correlated or not. Indeed, a recent re-evaluation
of 25 primary and secondary prevention statin trials suggested that the
CV benefit from statins are not mediated through pleiotropic effects but
rather only through their LDL-C lowering effect [80]. The earliest posi-
tive evidence stems from the CARE (Cholesterol and Recurrent Events)
trial involving patients with post-MI in which pravastatin reduced CRP
levels independent of the magnitude of LDL-C reduction [81]. Con-
versely, from the 2-year JUPITER study, in which LDL-C and hs-CRP re-
ductions were only weakly correlated, it appeared that reduction in both
LDL-C and hs-CRP are indicators of successful treatment with statins
[82]. However, for the same reduction of LDL-C (<70mg/dL) the mag-
nitude of benefit was superior in those achieving hs-CRP<1mg/dL
compared to hs-CRP<2mg/dL, i.e. 65% and 79% reductions in vascu-
lar events, respectively [83].
In a review article assessing the correlation between LDL-C low-
ering and inflammatory changes [84], the most prominent hs-CRP
reduction occurred in a study with extreme baseline hs-CRP elevation
[85]. High intensity statins provided the highest CRP lowering: in the
REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering)
Study, an IVUS comparative evaluation of plaque progression, atorvas-
tatin treatment reduced CRP (not hs-CRP) by 35.6% vs 5.2% for pravas-
tatin [86]. In the very large Heart Protection Study, investigating the
preventive activity of simvastatin [87], the reduction in vascular deaths
appeared instead to be independent of baseline hs-CRP levels.
Concerning plaque development, in a virtual histology (VH) intravas-
cular ultrasound study, there was clear evidence that changes of hs-CRP
had a significant positive correlation with reductions in the percent
necrotic core, percent dense calcium volume and absence of thin cap fi-
broatheroma, and a negative linear relationship with changes in percent
fibrous and percent fibro-fatty volumes [88]. In contrast, LDL-C changes
were not associated with any of these. This evidence should be consid-
ered when evaluating the conclusions of the GLAGOV (GLobal Assess-
ment of Plaque reGression With a PCSK9 antibOdy as Measured by in-
traVascular Ultrasound) study, reporting that addition of evolocumab to
statins did not result in any VH change [89]. At another arterial site, i.e.
the carotid artery, in neurologically asymptomatic patients, narrowing
of >50% associated with elevated hs-CRP gave the best prognostic in-
formation [90]. Evaluation of the coronary wall thickness by a similar
ultrasound method, together with hs-CRP, may offer a useful non inva-
sive approach to the determination of CV risk [91].
5. PCSK9 antagonists and hs-CRP
Although it is undoubted that the use of PCSK9 inhibitors is as-
sociated with a significant reduction of major adverse cardiovascular
events (MACEs) [relative risk: 0.83; 95%CI 0.78–0.88] [92] with my-
ocardial infarction [odds ratio (OR): 0.72 (95%CI: 0.64–0.81)], stroke
[OR: 0.80 (95%Cl: 0.67–0.96)] and coronary revascularization [OR:
0.78 (95%Cl: 0.67–0.96)] [93] driving this effect (number needed to
treat (NNT)/2years=89) [94], at the same time, it is evident that
these new agents do not impact either on hs-CRP levels [95]. A re-
cent meta-analysis on 10 RTCs, not comprising the cardiovascular out-
come trials (CVOT), found that short-term PCSK9 inhibitory treatment
did not reduce hs-CRP concentrations, irrespective of the type of an-
tibody (evolocumab, alirocumab or bococizumab) and patient charac-
teristics (FH, non-FH, ACSVD). Similar results were found when data
were corrected for age, sex and LDL-C lowering [96]. These findings do
not confirm previous conclusions, showing that non-statin lipid lowering
treatments result in significant hs-CRP reductions only in patients with
baseline levels above 2mg/L [84]. However, being most of the patients
in the PCSK9 trials on maximally tolerated statin therapy or on standard
care lipid lowering therapies, baseline hs-CRP may not reflect the true
residual inflammatory risk. Unfortunately, when PCSK9 inhibitors were
given as monotherapy in statin intolerant patients (ODYSSEY ALTERNA-
TIVE [97], in the GAUSS-1, -2 and -3 [98−100] RCTs) or in hypercho-
lesterolemic patients (MENDEL and MENDEL-2 RCTs), data on hs-CRP
were missing at follow-up. The only exception was the GAUSS-2 study
reporting that, against an LDL-C reduction of about 50%, hs-CRP was
lowered from 1.8 (0.9–3.3) to 1.5 (0.8–3.2) mg/L [99]. In the GAUSS-3
and ODYSSEY ALTERNATIVE baseline levels were 1.7mg/L.
Since a significant number of patients go on to have recurrent events
or show progression in IVUS studies, secondary analyses of the FOURIER
and SPIRE studies clearly demonstrated that, in spite of the dramatic
lowering of LDL-C to below 30mg/dL, hs-CRP remained a risk marker
across all categories of achieved LDL-C: the higher the baseline lev-
els, the larger risk reduction [9]. These data
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suggest that drivers of inflammation other than LDL-C contribute to
residual events in secondary prevention [101]. This general observation
has made the relationship between PCSK9 and the arterial inflammatory
process a matter of intensive debate. While inflammation raises PCSK9
liver expression [102] and PCSK9 is positively linked to TNF-α levels
[55], there is no clear relationship between PCSK9 levels and hs-CRP.
In the FOURIER (Further Cardiovascular Outcomes Research with
PCSK9 Inhibition in Subjects with Elevated Risk) study, recruiting sta-
ble CAD patients (LDL-C>70mg/dL), hs-CRP>2.0mg/dL was listed
as a minor risk factor among inclusion criteria [103]. Basal hs-CRP
levels were 1.7mg/L and 1.8mg/L in the evolocumab and placebo
groups, respectively; 29% had hs-CRP values<1mg/L, 41% between
1 and 3mg/dL and 30%>3mg/dL (Table 1). CV benefit was pre-
sent across the different baseline hs-CRP strata and patients with the
highest absolute risk reduction were those in the highest hs-CRP stra-
tum: 1.6% (<1mg/L), 1.8% (1–3mg/L) and 2.6% (>3mg/L). The
corresponding NNTs to prevent a primary endpoint event at 3 years
were 56 and 38, respectively, in patients with baseline hs-CRP lev-
els of 1–3mg/L and >3mg/dL (Table 2A). Considering hs-CRP mean
changes were −0.2mg/L in both treatment arms, the largest absolute
CV risk decrement was found in patients with base
line hs-CRP > 3mg/L. This post hoc analysis allows to identify individ-
uals getting the largest benefit from PCSK9 antagonists; even in those
achieving an on-treatment LDL-C of <20 mg/dL there was a 3-year
stepwise risk increment according to the baseline values of hs-CRP:
+9% (hs-CRP < 1 mg/L), +10.8% (hs-CRP 1–3 mg/L) and +13.1%
(hs-CRP > 3 mg/L) [104]. Moreover, event rates were lowest in pa-
tients achieving the lowest levels of both LDL-C and hs-CRP. To sum-up,
baseline hs-CRP levels do not modify the lipid effects of evolocumab
but do identify a group with a higher risk for CV disease, associated
with a lower NNT. A higher baseline hs-CRP associates to a higher
prevalence of other CV risk factors, e.g. hypertension, diabetes melli-
tus, smoking, and renal dysfunction, and a higher rate of comorbid con-
ditions, e.g. prior stroke and peripheral artery disease [104]. Briefly,
in the FOURIER study, according to hs-CRP strata (<1mg/L, 1–3mg/
L and >3mg/L) hypertension was present in 76%, 81% and 84%, re-
spectively; diabetes mellitus was found in 31%, 36% and 43%, respec-
tively, and finally smoking was reported in 23%, 29% and 32%, respec-
tively [104]. Thus, the use of a similar risk-stratification strategy with
an even broader range of factors can ensure that PCSK9 inhibitors are
made available to those with more to gain.
Table 1
Percentage changes of hsCRP and LDL-C upon drug treatments.
Clinical study hs-CRP (mg/L) LDL-C (mg/dL)
Pre post Δ pre post Δ
Monoclonal antibody anti IL-1β
Canakinumab CANTOS [4] 4.3 2.0 −37% vs. placebo 82.4 84.7 +3.1% vs. placebo
PCSK9 monoclonal antibodies
Evolocumab FOURIER [104] 1.7 1.4 0% vs. placebo 92.0 30.0 −59% vs. placebo
Bococizumab SPIRE-1 and -2 [101] 1.88 1.84 Mean change: +6.6% vs placebo at week 14 (median
change 0%);
+6.7% at week 52
96.5 34.7 −60.5% vs. placebo
(week 14).
Alirocumab ODYSSEY COMBOII
[149]
3.58 3.51 −2% vs. baseline 108.0 53.3 −49.5% vs. baseline
Alirocumab ODYSSEY OUTCOMES
[107]
1.6
(0.8–3.9)
not
available
not
available
87.0 53.0 −54.7% vs. placebo
Table 2
Analysis of the FOURIER (A) AND SPIREs (B) studies according to hs-CRP stratification.
(A)
FOURIER [104]
Primary Endpoints Secondary Endpoints
hs-CRP strata (mg/L) ARR RRR (HR) NNT ARR RRR (HR) NNT
<1 (0.6; 0.4–0.8) 1.6% (−0.5 – 3.7) 0.82 (0.70–0.95) – 0.8% (−1.1 – 2.7) 0.81 (0.66–0.99) –
1-3 (1.7; 1.3–2.3) 1.8% (0–3.5) 0.93 (0.83–1.05) 56 2.0% (0.4–3.4) 0.87 (0.75–1.02) 50
>3 (5.4; 3.9–8.8) 2.6% (0.4–4.9) 0.80 (0.71–0.90) 38 3.0% (1.0–5.0) 0.73 (0.63–0.85) 33
ARR, absolute risk reduction; hs-CRP, high-sensitivity C-reactive protein; HR, hazard ratio; NNT, number need to treat; RRR, relative risk reduction.
SPIRE-1 and -2[101]
hs-CRP strata (mg/L) HR for future CV events LDL strata (mg/dL) HR for future CV events
<1 (0.7; 0.4–1.2) 1 (REF) <30 1 (REF)
1-3 (1.8; 1.1–2.9) 1.16 (0.81–1.66) 30–50 0.87 (0.62–1.22)
>3 (4.7; 2.7–7.6) 1.62 (1.14–2.30) >50 1.21 (0.87–1.68)
REF, reference value.
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Evidence of residual inflammatory risk was particularly evident in a
post hoc analysis of SPIRE- 1 and -2 (Studies of PCSK9 Inhibition and
the Reduction of Vascular Events) trials with bococizumab, enrolling ei-
ther patients with a previous CV or a history of familial hypercholes-
terolemia (high-risk primary prevention cohort). When data from the
two studies were pooled, baseline levels of hs-CRP were 2.0mg/L in
both bococizumab and placebo arms with some differences upon sep-
arate evaluations: SPIRE-1: 1.8 vs 1.7mg/dL and SPIRE-2: 2.3 vs 2.3
(Table 1). Overall, patients with higher hs-CRP were those with con-
comitant CV risk factors, e.g. diabetes mellitus, diagnosed hypertension
or current smokers. When examining findings in more detail, against
a mean −60.5% fall in LDL-C, a +6.6% rise in hs-CRP was found in
the bococizumab arm. Despite the magnitude of LDL-C lowering, when
the analysis was stratified according to on-treatment levels of hs-CRP
a continuous gradient in risk for future CV events was found. Adjusted
hazard ratios (HRs) for future CV events were 1.0 (hs-CRP <1 mg/L),
1.16 (hs-CRP 1–3 mg/L) and 1.62 (hs-CRP >3 mg/L) (Table 2B). The
percentage of patients allocated to each group were 30.4%, 34.8% and
34.9%, respectively. Interestingly, if only LDL-C changes are considered
HRs are 1.0 (LDL-C<30mg/dL), 0.87 (LDL-C 30–50mg/dL) and 1.21
(LDL-C >50mg/dL) (Table 2B) [101].
The most recently published ODYSSEY OUTCOMES with alirocumab,
recruiting ACS patients, 89.5% on high intensity statins, reported in-
stead that the primary CV end points were reduced by 19% in the group
with hs-CRP < 2mg/L (HR: 0.81; 95%CI 0.71–0.92) and by a non-sig-
nificant 11% in the group with hs-CRP>2mg/L (HR: 0.89; 95%CI
0.79–1.01) (Table 1) [105]. No absolute changes for hs-CRP have been
reported in this and, so far, there are no further sub-analyses aimed
at exploring the impact of inflammation even after the achievement
of very low LDL-C. Nevertheless, it has now become clear that also in
the ODYSSEY OUTCOMES trial baseline hs-CRP levels identify subjects
at higher risk. Among 18,924 patients with a recent ACS, alirocumab
was superior to placebo to reduce first post-randomization MI by 15%:
−13% relative to type 1 MI and −23% relative to type 2 MI. Compared
to the subgroup with no MI event (17,719), patients who experienced
a post-randomization MI had higher baseline levels of LDL, Lp(a) and
hs-CRP. Across the three subgroups “no event”, “first event=type 1”
and “first event=type 2”, LDL-C (mg/dL) were 86, 91 and 91, respec-
tively; Lp(a) (mg/dL) 20.8, 25.4 and 34.9, respectively and hs-CRP (mg/
L) 1.6, 2.3 and 2.6, respectively. These parameters did not differ statis-
tically between type 1 and type 2 MI [106].
A further benefit of alirocumab over placebo has been the reduc-
tion in the all-cause deaths, 3.5% vs 4.1%, respectively, with an HR of
0.85 (95%CI: 0.73–0,98). Among survivors, median baseline hs-CRP lev-
els were 1.6mg/L (similar to the whole cohort) compared to 2.8mg/L
in those who died. Conversely, when the analysis was restricted to the
8,242 patients eligible to maintain the treatment for ≥3 years, against
a more pronounced benefit of alirocumab on all-cause death [HR 0.78
(95%CI: 0.65–0.94)] no between-group differences were found in basal
hs-CRP levels (1.6 vs 1.7mg/L) [107].
Finally, in the post-hoc analysis evaluating whether the efficacy of
alirocumab was influenced by the presence of polyvascular diseases,
higher levels of LDL-C, Lp(a) and hs-CRP were more pronounced in
the presence of two or three affected vascular beds. According to this,
LDL-C (mg/dL) was 86 (monovascular disease), 91 (coronary + pe-
ripheral artery disease), 90 (coronary + cerebrovascular diseases) and
95 (coronary + peripheral artery and cerebrovascular diseases); Lp(a)
(mg/dL) was 20.8, 25.5, 23.0 and 29.4, respectively and hs-CRP was 1.6,
2.6, 2.2, and 2.1, respectively [108].
Concerning alternative therapeutic strategies which modulate PCSK9
levels, inclisiran is a siRNA that acts by reducing both the intracellular
and extracellular PCSK9 levels. Upon its s.c. administration, inclisiran
leads to plasma lipoprotein changes quite similar to those mediated by
the anti-PCSK9 monoclonal antibodies [109]. Relative to hs-CRP, pa-
tients receiving a single dose of inclisiran 300 or 500mg had non-signif-
icant reductions of 16.2% and 19.8%, respectively, with a wide distrib-
ution. Conversely, patients at a two-dose regimen of inclisiran (300mg)
showed a 16.7% significant decrement in hs-CRP [110]. In the con-
text of atheroma formation, theoretically, inclisiran should result in a
lower amount of PCSK9 able to penetrate plaques, with no impact on
local PCSK9 production by macrophages and smooth muscle cells in the
atheroma (Fig. 2) [111].
More recently, in order to better assess mechanisms and conse-
quences of PCSK9 inhibition, a comparison between a genetic lower
Fig. 2. Presence of PCSK9 in the atheroma upon inhibition by monoclonal antibodies or siRNA (inclisiran). (Upper panel) Monoclonal antibodies bind PCSK9 leading to its circulation in
immune complexes either free or bound to LDL. These complexes may enter atheromas. (Lower panel) siRNA does not affect the local production of PCSK9 by macrophages and smooth
muscle cells in the atheroma, but it reduces the amount of circulating PCSK9 penetrating plaques. mAbs, monoclonal antibodies; siRNA, silencing RNA. Modified with permission fromEl-
sevier [111].
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ing of PCSK9 and that occurring after statin treatment was carried out
[112]. Individuals with a loss of function allele of PCSK9 had a reduced
lowering of VLDL-cholesterol compared to statin therapy (−54 vs −77%
reduction) for an equivalent lowering of LDL-C. This study also evalu-
ated a novel biomarker for future CV events. GlycA is part of the mam-
malian genome: glycans are attachments known to functionally modify
cytokines and other inflammatory proteins. Among these, GlycA quanti-
fies the NMR signal that originates from a number of plasma glycopro-
teins and was hypothesized to be a clinical marker of systemic inflam-
mation [113]. By standardized NMR a 17-year follow up of 27,490 in
the Women's Health Study showed a clear association between increased
GlycA levels and risk of all cause, CV and cancer mortality [114]. The
JUPITER study also showed that levels of GlycA associate with CV risk,
independent of hs-CRP and reduced by rosuvastatin [115]. In contrast,
genetic lowering of PCSK9 was not associated with any change of GlycA
[112]; no data were given on CRP.
6. PCSK9 antagonism benefit in high-risk populations
A number of reports have evaluated the potential benefit of PCSK9
antagonists in conditions not strictly related to LDL-C. An important case
is that of human immunodeficiency virus (HIV) infection, a global epi-
demic affecting 37 million people worldwide. While modern drug ther-
apy has improved HIV patient survival, the rate of MI among affected
individuals has risen by 50% [116]. In these subjects, chronic inflam-
mation, together with immune activation, have been reported as a possi-
ble trigger of the accelerated HIV-related atherosclerosis process [117].
However, since no clear mechanisms have been described identifying
non-traditional CV risk factors, elevated PCSK9 levels may provide an-
other cue to an improved understanding [118]. Indeed, in HIV+ pa-
tients not on antiretroviral therapy (ART), PCSK9 levels were signifi-
cantly elevated compared to matched HIV− subjects, an effect not re-
lated to the ART. Interestingly, PCSK9 associates with infection severity
only when patients are not on ART, whereas it is lost after ART initia-
tion. In spite of this dichotomy, no statistical correlations between PC-
SK9 and hs-CRP or IL-6 were found in HIV+ patients either before or
after ART initiation [119]. Quite similar conclusions were reached in
HIV/HCV-coinfected patients [120] and in a Swiss cohort of HIV pa-
tients not on statin treatment [121]. In this last case, marijuana con-
sumption and low CD4 values were associated with higher PCSK9 lev-
els, although PCSK9 did not correlate with hs-CRP or other inflamma-
tory markers, e.g. IL-8 or IL-10. Altogether this evidence highlights that
the expression of PCSK9 may be altered by the inflammatory milieu,
as was also found in patients with sepsis [122] or in those with severe
trauma injury [123]. Currently two trials with PCSK9 inhibitors are be-
ing carried out: (i) the EPIC-HIV (effect of PCSK9 inhibition on CV Risk
in treated HIV Infection) study evaluating the effect of alirocumab on
vascular inflammation, endothelial function, and non-calcified plaques
and (ii) the BEIJERINCK (Evolocumab Effect on LDL-C Lowering on
Back-ground Statin Therapy) study testing the efficacy of evolocumab in
HIV+ subjects with hyperlipidemia and/or mixed dyslipidemia.
A further case is that of diabetic patients, not only at an increased
risk of developing ASCVD but encountering worse outcomes when AS-
CVD is already present. Specifically, type 2 diabetes patients show a rise
in levels of markers and mediators of inflammation and acute-phase re-
actants including CRP, IL-6 and fibrinogen [124]. Considering that in
insulin-resistant patients PCSK9 associates with the secretion rate of in-
testinal lipoproteins and that PCSK9 loss-of-function carriers have re-
duced levels of fasting and postprandial TG [125], this may be the
mechanism by which PCSK9 may mediate the atheroma inflamma-
tory burden in diabetics. Indeed, TRL remnants induce endothelial dys-
function, inhibit fibrinolysis, and enhance co
agulation and vascular inflammation [38]. Aside from the post-hoc
analysis of the FOURIER study showing that evolocumab in patients
with diabetes resulted in higher absolute risk reduction in the primary
endpoint/coronary revascularization, i.e. −2.7% in patients with dia-
betes vs −1.6% reduction in non-diabetic patients [126], results of the
recent BANTING (The evolocumaB efficAcy aNd safeTy IN type 2 dia-
betes mellitus on backGround statin therapy) study supports the efficacy
and safety of evolocumab in patients with type 2 diabetes mellitus, hy-
perlipidemia or mixed dyslipidemia. Among 280 out of 421 individuals
given evolocumab for 12 weeks, LDL-C was decreased by 54–65% and
non-HDL-C by 47–57%, more patients reaching an LDL-C < 70mg/dL or
an LDL-C reduction ≥50%. A benefic was also found for Lp(a) (−32.6%),
triacylglycerol (−13.7%) and VLDL-C (−13.3%), data confirmed in the
post-prandial state [127]. The consistency of these findings also relies
on the recent knowledge highlighting how in high-risk patients with di-
abetes and already at statins, an incremental attainment of ASCVD risk,
independent of LDL-C changes, is observed in patients experiencing the
higher reductions of VLDL and their associated cholesterol [128].
In the case of alirocumab, in ODYSSEY OUTCOMES study patients
with diabetes (28.8%) randomized to alirocumab had the largest ab-
solute risk reduction, i.e. 2.3% vs 1.2% in those with prediabetes or with
normal glycemia [129].
7. Discussion
Persistence of a high risk of CV events following ACS in optimally
drug and revascularization treated patients has indicated that other vari-
ables may account for the increased risk [130]. Availability of novel
powerful lipid lowering agents, i.e. PCSK9 inhibitors in addition to
statins, allowed to evaluate their activity on both lipids and inflamma-
tory markers, that are mainly characterized by elevated levels of hs-CRP,
a biomarker of CV risk although not playing a clear causal role in ath-
erosclerosis. Another still debated issue is the clinical relevance of mea-
suring circulating PCSK9 levels. Indeed, this protein is closely regulated
at the transcriptional and translational levels, leading to concentrations
varying over an approximately 100-fold range (reviewed in Ref. [109]).
In a large Swiss multicenter cohort of patients hospitalized for ACS,
higher PCSK9 levels were associated with a higher degree of inflam-
mation, as assessed by hs-CRP, but they did not predict mortality at 1
year. Conversely, data from an observational study did not find any as-
sociation between PCSK9 and hs-CRP in spite of a positive association
with the severity of coronary artery lesions [131,132]. In a most recent
study PCSK9 levels were found to predict the occurrence of ACS in pa-
tients with severe carotid artery stenosis, the best predictive values be-
ing above 431.3mg/dL [133].
Turning back to a pharmacological clinical approach, in spite of the
general suggestion that PCSK9 inhibitors should be recommended only
after an initial 2–3 month run-up treatment adaptation with maximally
tolerated statin doses, an earlier initiation of PSCK9 mAb treatment may
be justified by the evidence that in the acute phase of ACS PCSK9 may
raise coronary plaque vulnerability, inflammation and platelet aggrega-
tion [130]. Then, findings from the EVOPACS [EVOlocumab for Early
Reduction of LDL-cholesterol Levels in Patients With Acute Coronary
Syndromes (NCT03287609)] trial will certainly shed light on this matter
[134].
The two major variables resulting from lipid lowering medications,
i.e. reduction of LDL-C and hs-CRP in ASCVD patients appear to be
additive as independent predictors [135,136]. In major statin trials,
e.g. the JUPITER study with rosuvastatin, maximal benefit was ob-
served in patients achieving reduced levels of both variables, i.e. LDL-C
< 70mg/dL and hs-CRP < 2mg/L. The validity of this conclusion
has been confirmed by statin and non-statin therapies aimed
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to lowering LDL-C, e.g. the PROVE-IT trial showing that patients who
attained LDL-C below 70mg/dL and hs-CRP < 2mg/dL derived the
largest clinical benefit [137]. The successful achievement of the dual
goal was highlighted again in the IMPROVE-IT study in which patients
achieving both targets had lower recurrence of CV events than those
meeting neither, i.e. −38.9% vs −28.0%, respectively [138]. Since con-
comitant reductions of hs-CRP and LDL-C appear to lead to maximal
benefit [139], appropriate clinical studies, e.g. with a 2X2 factorial de-
sign, with aggressive LDL-C-lowering and anti-inflammatory therapies
are eagerly awaited [140]. This hypothesis has become of critical inter-
est after the divergent conclusions of the REGARDS (Reasons for Geo-
graphical and Racial Differences in Stroke) study in which in high-risk
patients the variable mainly associated with a CV risk reduction was
hs-CRP<2mg/dL with no further protective effect when LDL-C was
<70mg/dL [141]. Indeed, the two variables appear to be linked to
different morphological vascular outcomes. Whereas reduced hs-CRP is
linked to anatomical changes in the atheroma [88,142], i.e. reduced
percent necrotic core and absence of thin cap macroatheroma, this is not
found with just LDL-C changes [89]. In the virtual histology evaluation
of the GLAGOV study with evolocumab, this did not lead to meaning-
ful reductions in hs-CRP levels [89]. Interpretation of findings from the
GLAGOV study, however, should consider that coronary patients were
on statin background, and that HMGCo-A reductase inhibitors are as-
sociated per se with a slower progression of coronary atheromas, with
increased plaque calcification and reduction of high-risk plaque fea-
tures [143]. In the near future, findings from other ongoing RCTs will
certainly shed light on the correlation between PCSK9 inhibition and
plaque regression.
8. Conclusions
In the context of an optimal treatment strategy aimed at reducing CV
risk, it is useful to identify effects that are specific or shared by either
lipid lowering drugs, or anti-inflammatory drugs or a combination of
both [139,144]. Moreover, since association studies do not necessarily
imply a causal role of PCSK9 in the inflammatory response [145] and
data from carriers of loss-of-function mutations in PCSK9, aimed to es-
tablish a correlation between plasma inflammation markers and PCSK9
levels, are scanty and not conclusive [146,147], evidence from the ef-
fects of anti-inflammatory molecules on PCSK9 levels might help to un-
ravel this hitherto complex tangle.
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